European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

On Friday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.41 which represents a decrease of $-0.51 or -0.85% from the prior close of $59.92. The stock opened at $59.81 and touched a ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...

(Reuters) - Contract drug manufacturer Catalent, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...

根据最近的SEC文件显示，Catalent, Inc. (NYSE:CTLT)的董事Ryan Michelle R近期出售了2,800股公司普通股。每股售价为59.70美元，总交易价值为167,160美元。此次出售后，Ryan Michelle R现持有10,835股，包括限制性股票单位。这些股票的出售是为了支付之前根据Catalent非雇员董事薪酬计划授予的限制性股票单位相关的税款。

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...